Exploding Pipeline Makes BioMarin Pharmaceutical Inc. (BMRN) Attractive Takeover Target

Page 1 of 2

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)The Orphan Drug pipeline of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been growing so rapidly that the company has been the object of many takeover rumors since 2006 when it was believed that Genzyme was eyeing them for a buyout. No buyout has occurred yet, but rumors persist and since 2006, shares have risen from $3.87 to over $70.  Further supporting this potential buyout is that Genzyme has been acquired by Sanofi SA (ADR) (NYSE:SNY), and Sanofi has expressed a strong interest in Orphan Drugs and even stated that they are a good pharma model.  If Sanofi’s Genzyme unit successfully acquires BioMarin, then it will add greatly to Sanofi’s pipeline of fast growing Orphan Drugs and help position Sanofi even stronger in this very high growth area.

There are two primary reasons for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s spectacular growth, and the first one is that they specialize in Orphan Drugs that have tremendous advantages over traditional drugs. Orphan Drugs are frequently priced very high and generate very large profit margins. The global Orphan Drugs market generated revenue of $84.9 billion in 2009 and is growing exceptionally fast, expected to reach $112.1 billion by 2014. Orphan Drugs may now the biggest growth driver for the pharmaceutical industry as big pharma is faced with the patent cliff of expiring patents for their aging pipelines.

Time for FDA approval can be accelerated or granted “Fast Track” status. Prices can often be reimbursed for over $100,000 per year per patient for treatment. An example is BioMarin’s Naglazyme with an annual per patient cost of $365,000. Clinical trials are far cheaper because there are fewer patients to study, dictating lower numbers of patients in the trials. According to Genetic Engineering News, Phase III trials for the top ten orphan drugs was 592 patients as opposed to 8,614 for their non-orphan counterparts.

The Orphan Drug Act provides federal tax credits of up to 50% of orphan drug research costs and provides seven-year exclusivity on drug sales for the first company to receive FDA marketing approval. The Orphan Drug Act can also provide for waivers for certain FDA fees including drug approval application and annual product fees.

Orphan drugs treat rare conditions and don’t require a large sales force therefore creating a much lower marketing cost. Thomson Reuters Research claims that about one third of orphan drugs make over $1 billion a year in sales. Collectively, these advantages for Orphan Drugs add up to very fast growth and fast-rising share prices.

The second big reason for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s strong growth is their underlying plan to acquire smaller companies that can enhance their pipeline cost-effectively. In January 2012, BioMarin CEO, Jean-Jacques Bienaime, said in an interview that BioMarin is seeking to buy smaller companies to expand its pipeline for treatment of rare diseases, but not to be acquired itself. Bienaime further said, the company will follow a similar acquisition strategy to one used for purchases such as Zystor Therapeutics Inc., which BioMarin bought in 2010 for $22 million in upfront cash. That acquisition gained the company a medicine now being tested for Pompe disease, a muscle-disabling disorder.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!